Results 101 to 110 of about 8,921 (227)

The effects of Lysergic Acid Diethylamide (LSD) on the Positive Valence Systems: A Research Domain Criteria (RDoC)-Informed Systematic Review. [PDF]

CNS Drugs, 2023
Pouyan N, Younesi Sisi F, Kargar A, Scheidegger M, McIntyre RS, Morrow JD.   +5 more
europepmc   +1 more source

Effect of lysergic acid diethylamide (LSD) on reinforcement learning in humans. [PDF]

Psychol Med, 2023
Kanen JW, Luo Q, Rostami Kandroodi M, Cardinal RN, Robbins TW, Nutt DJ, Carhart-Harris RL, den Ouden HEM.   +7 more
europepmc   +1 more source

Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity. [PDF]

Neuropsychopharmacology, 2023
Glazer J, Murray CH, Nusslock R, Lee R, de Wit H.   +4 more
europepmc   +1 more source

Psychedelic therapy from an existential psychological viewpoint : a theoretical analysis [PDF]

, 2016
Clinical research into the therapeutic applications of classical psychedelics has slowly but steadily resumed over the last couple of decades. Continuing the research that went dormant in the late 1960‟s, modern trials are looking into the use of high ...
Berg, Stian Hyman
core   +1 more source

Adverse experiences resulting in emergency medical treatment seeking following the use of lysergic acid diethylamide (LSD). [PDF]

J Psychopharmacol, 2022
Kopra EI, Ferris JA, Rucker JJ, McClure B, Young AH, Copeland CS, Winstock AR.   +6 more
europepmc   +1 more source

Lysergic acid diethylamide (LSD) promotes social behavior through mTORC1 in the excitatory neurotransmission. [PDF]

Proc Natl Acad Sci U S A, 2021
De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, Posa L, Lopez-Canul M, He Q, Lafferty CK, Britt JP, Comai S, Aguilar-Valles A, Sonenberg N, Gobbi G.   +14 more
europepmc   +1 more source

Annual Report of the Biological Laboratory [PDF]

, 1961
1960 ...
Chovnick, Arthur
core   +1 more source

Repeated lysergic acid diethylamide (LSD) reverses stress-induced anxiety-like behavior, cortical synaptogenesis deficits and serotonergic neurotransmission decline. [PDF]

Neuropsychopharmacology, 2022
De Gregorio D, Inserra A, Enns JP, Markopoulos A, Pileggi M, El Rahimy Y, Lopez-Canul M, Comai S, Gobbi G.   +8 more
europepmc   +1 more source

Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders

Pharmaceuticals
Psychedelics have recently (re)emerged as therapeutics of high potential for multiple mental health conditions, including substance use disorders (SUDs).
Tamara Valdez, Valbhi Patel, Nattaphone Senesombath, Zayd Hatahet-Donovan, Mary Hornick   +4 more
doaj   +1 more source

N, N-Dimethyltryptamine and Biological Reductive Accounts for Religious and Spiritual Experiences [PDF]

, 2014
There is unquestionably a plethora of details and mysteries regarding the mind and the body. However, with the advent of psychopharmacology (the study of how psychedelics inform or alter brain states), there are more issues at hand. Do psychedelics allow
Smith, Shaun
core   +1 more source